Get the Same Effective Dose With Less Estrogen Than Other Estrogen Therapies*

Vivelle-Dot® Offers Your Patients Lower Estrogen Content Than Oral or Other Branded Transdermal Estrogen Therapy (ET) Options

Vivelle-Dot requires a lower concentration of estrogen in the dosage form than the transdermal ET products listed below to achieve the same weekly dose.*

*This does not mean that there is any difference in safety or efficacy between Vivelle-Dot and other transdermal ETs

Estrogen content of transdermal systems†
Product Weekly Estradiol Applied Total Weekly Dose Amount Remaining in Dosage Form
Other Brand-Name Patches‡ 3.0-20.0 mg 0.35 mg 2.65-19.65 mg
Topical Lotion§ 60.9 mg 0.35 mg 60.55 mg
Vivelle-Dot‡ 1.56 mg 0.35 mg 1.21 mg

†0.05 mg/day dosage strength is not approved for gel and spray formulations.
‡Calculated based on 0.05 mg/day effective dose over a 7-day period.
§Calculated based on estradiol lotion formulation dosed at 0.05 mg/day effective dose over a 7-day period.

Vivelle-Dot Contains Smaller Total Doses Than Oral ETs

The highest dose of Vivelle-Dot is smaller than the lowest dose of conjugated estrogens. This does not imply differences in safety or efficacy.

Vivelle-Dot Contains Smaller Total Doses than Oral ET

||Vivelle-Dot 0.025 mg/day is indicated for the prevention of postmenopausal osteoporosis only.

Did you find this page helpful? Yes No

Vivelle-Dot has 4 Indications for Menopause

Vivelle-Dot, the #1 prescribed transdermal estrogen therapy, is FDA approved for 4 indications.
Learn more

Great Design with DOT Matrix® Technology

Delivery Optimized Thermodynamics (DOT) Matrix® Technology provides multiple benefits.
Learn more

Order Samples & Support Materials

Extensive patient support in and out of the office.
Learn more
  1. Vivelle-Dot (estradiol transdermal system) [prescribing information]. Novartis Pharmaceuticals Corporation; August 2004.

The information contained within this Web site is appropriate for U.S. healthcare professionals only. A visit to this site should not replace a visit to your doctor.
Copyright © 2011 Novogyne Pharmaceuticals. All rights reserved5/11 VVD-1051503

X
Tell A Colleague

Share information about Vivelle-Dot® by e-mailing this Web site to a colleague.

After clicking the "Send" button below, your colleague will receive an e-mail containing a link to this Web site.
* Required Fields
Continue Cancel
Leaving the Vivelle-Dot® Web Site

Continue Cancel